Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referenced as Newcelx Ltd. in metadata) covers the month of July 2025, with a specific report date of July 18, 2025. The filing reports on a corporate development regarding a proposed merger with Kadimastem Ltd.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a legal amendment to a merger agreement.
Material Changes
On July 18, 2025, the Company entered into a Sixth Amendment to the Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. The material changes include:
- Exchange Ratio Calculation: The components used to calculate the Exchange Ratio will now be determined based on information available as of the close of business on the day immediately prior to the extraordinary general meeting of the Company's shareholders.
- Clarification of Timing: The amendment clarifies timing references used in calculating the relative valuation of the Company and Kadimastem and the number of shares to be issued.
- Scope: No other substantive changes were made to the Merger Agreement.
Guidance, Outlook, and Risks
Management Commentary: The Parties remain fully committed to completing the merger as soon as possible with utmost diligence and are actively working to fulfill all regulatory commitments.
Risks and Contingencies: The filing includes a Safe Harbor Statement noting that forward-looking statements are subject to uncertainties. Key risks include:
- Failure to complete the merger on proposed terms or schedule.
- Failure to satisfy closing conditions or obtain timely shareholder approvals.
- Unexpected costs, charges, or expenses resulting from the transaction.
- Potential adverse reactions or changes to business relationships.
Unusual Items: None reported beyond the standard merger process risks.
Investor Verification Checklist
- Verify the full text of the Sixth Amendment filed as Exhibit 99.1.
- Review the Proxy Statement/Prospectus filed on Form F-4 (and subsequent amendments) for detailed transaction terms.
- Confirm the date of the extraordinary general meeting of shareholders, as this determines the Exchange Ratio calculation date.
- Check for any new amendments to the F-4 Registration Statement filed after June 23, 2025.
- Review the "Risk Factors" section in the Company's 2024 Form 20-F for broader risk context.